Session Information
Date: Saturday, October 6, 2018
Session Title: Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment
Session Time: 1:45pm-3:15pm
Location: Hall 3FG
Objective: The present study was designed in order to explore the possible synergistic effect of two highly naturally occurring bio-active compounds viz. Ellagic acid (EA) and Methanolic extract of Mucuna Pruriens Seeds (MPM). The neuroprotective role of combinational therapy of EA and MPM was explored in rotenone induced behavioural, oxidative and mitochondrial dysfunction in mice model of Parkinson’s disease.
Background: Ellagic acid (EA) and Mucuna Pruriens, are natural polyphenolic, powerful bioactive compounds used word wide. They exhibited numerous biological and pharmacological activities including potent antioxidant, cardiovascular disease, anticancer, anti-inflammatory effects and neurodegenerative disorders in cell cultures and animal models.
Methods: Chronic administration of rotenone (1 mg/kg i.p.) for a period of three weeks significantly impaired behavioural paradigm (Memory, learning and locomotor activity), oxidative defence (Decreased activity of superoxide dismutase, catalase and reduced glutathione level) and mitochondrial Complex-II-Succinate Dehydrogenase (SDH), Complex III- MTT (3- (4,5-dimethylthiazol-2-yl)-2,5-diphenyl-H-tetrazolium bromide) enzymes activities as compared to normal control group in the brain of mice.
Results: Three weeks of EA and MPM combination (50, 100 and 200 mg/kg, p.o) treatment significantly improved behaviour parameters (P < 0.001) oxidative damage (P < 0.001) and mitochondrial enzyme complex activities (< 0.05, P < 0.01, P < 0.001) as compared to negative control (rotenone treated) group. We found that combination of Cur and MPM restored motor deficits and enhanced the activities of antioxidant enzymes suggesting its antioxidant and neuroprotective potential in vivo.
Conclusions: The findings of present study concludes neuroprotective role of combination of EA and MPM against rotenone induced Parkinson’s in mice and offers strong justification for the therapeutic prospective of these compound in the management of PD.
References: Sarkaki A, Farbood Y, Dolatshahi M, Mansouri SM, Khodadadi A. Neuroprotective Effects of Ellagic Acid in a Rat Model of Parkinson’s Disease. Acta Medica Iranica. 2016 Sep 17;54(8):494-502. Manyam BV, Dhanasekaran M, Hare TA. Neuroprotective effects of the antiparkinson drug Mucuna pruriens. Phytotherapy Research. 2004 Sep 1;18(9):706-12.
To cite this abstract in AMA style:
D. Khatri. Combination Therapy of Ellagic Acid and Mucuna Pruriens Seeds Extract Improves Rotenone Induced Behavioural, Oxidative and Mitochondrial Deficits in Mice Model of Parkinson’s Disease [abstract]. Mov Disord. 2018; 33 (suppl 2). https://www.mdsabstracts.org/abstract/combination-therapy-of-ellagic-acid-and-mucuna-pruriens-seeds-extract-improves-rotenone-induced-behavioural-oxidative-and-mitochondrial-deficits-in-mice-model-of-parkinsons-disease/. Accessed November 22, 2024.« Back to 2018 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/combination-therapy-of-ellagic-acid-and-mucuna-pruriens-seeds-extract-improves-rotenone-induced-behavioural-oxidative-and-mitochondrial-deficits-in-mice-model-of-parkinsons-disease/